Circulating biomarkers such as BNP, NT-proBNP, MPO, GDF-15, troponin, sST2, and CA125 serve as valuable diagnostic indicators and offer prognostic insights for congestive heart failure management.
This review highlights the role of circulating biomarkers in the early diagnosis, treatment guidance, and prognostic assessment of heart failure.
心力衰竭是由心肌损伤、心脏前后负荷增大、炎性反应以及神经内分泌系统失调等多种原因导致的心脏结构或功能异常，是许多心血管疾病发展的终末阶段。尽管随着医疗水平的不断进步，心血管疾病的治疗策略得到巨大改进，但心力衰竭在世界范围内的发病率和死亡率仍然居高不下，对其进行早期诊断对治疗及改善预后至关重要。反映心力衰竭发生发展过程的病理生理途径中产生了一系列的循环生物标志物，这些生物标志物可以作为心力衰竭的诊断指标，并为后续治疗和评估预后提供指导依据。此文就心力衰竭生物标志物的研究进展进行综述。Heart failure is a manifestation of cardiac structural or functional abnormalities resulting from various etiologies, including myocardial injury, increased cardiac workload, inflammatory response, and neuroendocrine system disorders. It represents the advanced stage of numerous cardiovascular diseases. Despite significant advancements in treatment strategies for cardiovascular diseases, heart failure continues to exhibit high global morbidity and mortality rates. Therefore, early diagnosis plays a crucial role in guiding treatment interventions and improving prognosis. Pathophysiological pathways give rise to a series of circulating biomarkers that reflect the onset and progression of heart failure. These biomarkers serve as diagnostic indicators for heart failure and offer valuable insights for subsequent treatment decisions and prognostic assessments. This article provides an overview of recent research progress on heart failure biomarkers.
娜 孙 (Wed,) conducted a review in Congestive Heart Failure. Biomarkers (BNP, NT-proBNP, MPO, GDF-15, Troponin, sST2, CA125) was evaluated. Circulating biomarkers such as BNP, NT-proBNP, MPO, GDF-15, troponin, sST2, and CA125 serve as valuable diagnostic indicators and offer prognostic insights for congestive heart failure management.